[go: up one dir, main page]

CR8251A - Composiciones de hiv inmunogenicas y metodos relacionados - Google Patents

Composiciones de hiv inmunogenicas y metodos relacionados

Info

Publication number
CR8251A
CR8251A CR8251A CR8251A CR8251A CR 8251 A CR8251 A CR 8251A CR 8251 A CR8251 A CR 8251A CR 8251 A CR8251 A CR 8251A CR 8251 A CR8251 A CR 8251A
Authority
CR
Costa Rica
Prior art keywords
immunogenic compositions
hiv
antigen
related methods
hiv antigen
Prior art date
Application number
CR8251A
Other languages
English (en)
Inventor
B Moss Ronald
Original Assignee
Immune Response Corp Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immune Response Corp Inc filed Critical Immune Response Corp Inc
Publication of CR8251A publication Critical patent/CR8251A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La invencion proporciona composiciones inmunogenicas que mejoran la duracion y resistencia de la respuesta inmune en un mamifero. Las composiciones inmunogenicas continen un antigeno HIV, un inmunomero y un adyuvante. El antigeno HIV puede ser un virus HIV exterminado completo exento de proteina envolvente externa gp120. Alternativamente, el antigeno HIV puede ser un virus HIV exterminado completo. O un antigeno p24. Tambien se proporcionan equipos, los componentes de los cuales, cuando se combinan, producen las composiciones inmunogenicas de la invencion. La invencion tambien proporciona metodos para hacer las composiciones inmunogenicas, combinando un antigeno HIV, un inmunomero y opcionalmente un adyuvante.
CR8251A 2003-08-28 2006-02-22 Composiciones de hiv inmunogenicas y metodos relacionados CR8251A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US49880403P 2003-08-28 2003-08-28

Publications (1)

Publication Number Publication Date
CR8251A true CR8251A (es) 2008-09-23

Family

ID=34272731

Family Applications (1)

Application Number Title Priority Date Filing Date
CR8251A CR8251A (es) 2003-08-28 2006-02-22 Composiciones de hiv inmunogenicas y metodos relacionados

Country Status (14)

Country Link
US (2) US20070253979A1 (es)
EP (1) EP1670893A4 (es)
JP (1) JP2007523884A (es)
CN (1) CN101291691A (es)
AP (1) AP2006003530A0 (es)
AU (1) AU2004269379A1 (es)
BR (1) BRPI0413906A (es)
CA (1) CA2535527A1 (es)
CR (1) CR8251A (es)
IL (1) IL173740A0 (es)
MX (1) MXPA06001996A (es)
OA (1) OA13246A (es)
WO (1) WO2005021726A2 (es)
ZA (1) ZA200602246B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US20030026782A1 (en) 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
CN101948835A (zh) 2002-10-29 2011-01-19 科勒制药集团股份有限公司 Cpg寡核苷酸在治疗丙型肝炎病毒感染中的应用
JP2006512927A (ja) 2002-12-11 2006-04-20 コーリー ファーマシューティカル グループ，インコーポレイテッド ５’ｃｐｇ核酸およびその使用方法
WO2005089231A2 (en) * 2004-03-12 2005-09-29 Hybridon, Inc. Enhanced activity of hiv vaccine using a second generation immunomodulatory oligonucleotide
EP2344143A1 (en) 2008-09-09 2011-07-20 Mukesh Harilal Shukla Bioactive composition for the treatment of the hiv/aids, method for manufacturing and using the same
AU2011259718B2 (en) * 2010-05-28 2016-03-03 Zoetis Belgium S.A. Vaccines comprising cholesterol and CpG as sole adjuvant - carrier molecules
CN107899009B (zh) * 2011-04-06 2021-09-17 拜欧瓦克西姆有限公司 用于预防和/或治疗人中的hiv疾病的药物组合物
CA2832022C (en) * 2011-04-06 2019-01-08 Biovaxim Limited Pharmaceutical compositions for preventing and/or treating an hiv disease in humans
BR112016015736B1 (pt) 2014-01-08 2022-01-04 Immunovative Therapies, Ltd. Uso de um aloantígeno, uma molécula que interage com receptor de superfície cd40 e citocinas tipo i; e pelo menos um ou mais antígenos de hiv, kit, composição e composição de avi
TWI714529B (zh) * 2015-05-20 2021-01-01 以色列商梵提夫免疫療法公司 人類免疫缺乏病毒/後天性免疫缺乏症候群之治療

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000067787A2 (en) * 1999-05-06 2000-11-16 The Immune Response Corporation Hiv immunogenic compositions and methods
EP1355663A1 (en) * 2001-01-26 2003-10-29 The Immune Response Corporation Method for treating an hiv-infected individual by combining immunization with structured interruption of anti-retroviral treatment
CA2532926A1 (en) * 2003-07-15 2005-02-03 Hybridon, Inc. Combined use of immunostimulatory oligonucleotides and cytokines or radiation

Also Published As

Publication number Publication date
WO2005021726A3 (en) 2008-01-17
JP2007523884A (ja) 2007-08-23
BRPI0413906A (pt) 2006-10-24
AU2004269379A1 (en) 2005-03-10
AU2004269379A2 (en) 2005-03-10
CN101291691A (zh) 2008-10-22
EP1670893A2 (en) 2006-06-21
IL173740A0 (en) 2006-07-05
WO2005021726A2 (en) 2005-03-10
EP1670893A4 (en) 2008-09-03
ZA200602246B (en) 2007-05-30
OA13246A (en) 2007-01-31
CA2535527A1 (en) 2005-03-10
MXPA06001996A (es) 2006-06-20
AP2006003530A0 (en) 2006-02-28
US20070253979A1 (en) 2007-11-01
US20050196411A1 (en) 2005-09-08

Similar Documents

Publication Publication Date Title
ATE426412T1 (de) Adjuvante influenza-vakzine
CR6491A (es) Composiciones y metodos inmunogenicos de hiv
ATE501726T1 (de) Zusammensetzung mit immunogenen mikroteilchen
CR8251A (es) Composiciones de hiv inmunogenicas y metodos relacionados
AR080216A2 (es) Composiciones farmaceuticas que contienen una proteina de fusion de vih
NO20023829L (no) Proteosom influensavaksine
EA200801798A1 (ru) Виросомоподобные везикулы, содержащие антигены, производные от gp41
CY1115308T1 (el) Συνθεσεις εμβολιου οι οποιες περιεχουν ανοσοενισχυτικο εκδοχο σαπωνινης
HN2001000027A (es) Derivados de purina
EA200700904A1 (ru) Вакцины против вируса японского энцефалита и вируса западного нила
CY1113546T1 (el) Μικρορευστοποιημενα γαλακτωματα ελαιου σε νερο και συνθεσεις εμβολιων
DK1401489T4 (da) Solubilisering af kapselpolysaccharid
BR122018075729B8 (pt) flavivírus na preparação de uma composição de vacina
FR16C0014I2 (fr) Vaccin contre le virus de la fievre du nil
BR0108210A (pt) Vacina contra o vìrus da imunodeficiência humana
CY1110744T1 (el) Ανοσοδιεγερτικος συνδυασμος για την προφυλακτικη και θεραπευτικη αντιμετωπιση της ηπατιτιδας c
DK1387681T3 (da) Anvendelse af castanosperinderivater til behandling af hepatitis C
CL2004000807A1 (es) Composicion de extraccion por solvente que comprende una o mas ortohidroxiarilaldoxinas y una o mas ortohidroxiarilcetoxinas y uno o mas modificadores de equilibrio para producir un grado de modificacion de las ortohidroxialrilaldoximas, de aproximad
ATE458496T1 (de) Hiv-vakzine und anwendungsverfahren
CY1106310T1 (el) Καθορισμος hbv αντιγονων για χρηση σε εμβολια
ATE419008T1 (de) Adjuvante zusammensetzung und anwendungsverfahren dafür
WO2009044272A3 (en) Laser-based vaccine adjuvants
MX2008001597A (es) Formulaciones novedosas que comprenden fenofibrato y una estatina y metodos relacionados de tratamiento.
DK1765337T3 (da) Kombination af tenofovir, ritonavir og TMC114
BRPI0417265A (pt) composição farmacêutica compreendendo um princìpio ativo e sulfobetaìna

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)